MD Anderson Cancer Center has settled two separate trademark suits protecting the Houston-based cancer center's Moonshot program.
Under ordinary circumstances, a $12 million gift from a charitable foundation to a university is a cause for celebration.
The MD Anderson complaint against Patrick Soon-Shiong and his business entities, filed Nov. 30, 2016, in the U.S. District Court for the Southern District of Texas, argues that the controversial billionaire's use of the moonshot trademark created confusion that affected both MD Anderson and the White House initiative headed by then Vice President Joe Biden.
Overnight, cancer pharmaceuticals billionaire Patrick Soon-Shiong stopped using the trademark “MoonShot” to describe his health initiatives, opting instead to use the less grabby, but equally ambitious, name “cancer breakthroughs.”
Government agencies said the biotechnology billionaire Patrick Soon-Shiong had overstated the extent of their involvement in “Cancer MoonShot 2020,” the immunotherapy clinical trials program he put together.
PATRICK SOON-SHIONG was named global director for cancer services and bioinformatics of Providence Health & Services.
ImmunityBio Inc. and NCI are partnering to open a clinical trial to study ImmunityBio’s investigational Tri-Ad5 vaccine combination (Adenovirus 5 CEA/MUC1/brachyury) together with its IL-15 superagonist N-803, an immune-enhancer, for people with Lynch syndrome.
A multi-institutional team led by scientists from the Medical College of Wisconsin Cancer Center has discovered PD-L2 as a therapy-relevant marker to identify patients with estrogen receptor-positive breast cancer who may benefit from new immunotherapies.
Are Ibram X. Kendi, Charles Dickens, and Nobel Laureate Paul Nurse on your bookshelf, too?
The American Association for Cancer Research has established the Cancer Evolution Working Group.